Replies to post #191721 on Biotech Values

[DewDiligence]

Thx for feedback. Based on JNP's CC, management thinks the future of the company lies in the newly in-licensed (potentially multi-drug) IVR. Crinone and the existing delivery mechanism will keep the company funded while it develops the IVR for applications that have yet to be disclosed.

[DewDiligence]

JNP—COL-1077 (vaginal lidocaine) fails phase-2b trial:

http://finance.yahoo.com/news/juniper-pharmaceuticals-reports-results-phase-212500771.html

This Phase 2b randomized, double-blinded, placebo-controlled, multi-center clinical trial was designed to evaluate the safety and efficacy of COL-1077 10% lidocaine bioadhesive vaginal gel compared to a placebo bioadhesive gel for the reduction of pain intensity in women undergoing pipelle-directed endometrial biopsy with tenaculum placement. The primary efficacy endpoint was reduction in pain intensity at the time of endometrial biopsy on a validated 0-10 Numerical Pain Rating Score (NPRS), with secondary endpoints assessing the reduction in post-procedural pain and cramping over a 24-hour time period.

JNP will now focus on the IVR platform described in #msg-114026617.